The latest news, announcements and press releases from BlueWhale Bio.
RADNOR, Pa. and PHILADELPHIA, Oct. 15, 2025 — Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced a strategic partnership with BlueWhale Bio, a commercial-stage company dedicated to transforming immune cell therapy manufacturing and addressing the unmet need in CAR-T production by streamlining manufacturing, reducing variability, and shortening time-to-patient.
The partnership combines Avantor’s bioprocessing and custom ancillary-reagent manufacturing capabilities with BlueWhale Bio’s Synecta™ cell-derived nanoparticle (CDNP) platform, which mimics natural T-cell stimulation. The collaboration aims to accelerate CDNP manufacturing scale-up to help CAR-T developers significantly reduce expansion time – potentially expanding patient access and manufacturing capacity across the growing cell therapy sector. Together, the teams will produce GMP-grade CDNP materials to support this next-generation manufacturing approach.
This is the News section of the company profile page for BlueWhale Bio on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
